Novartis has signed an agreement to acquire the specialty generic injectables business of Ebewe Pharma for $1.2 billion. The deal covers Ebewe’s injectable oncology unit, but excludes Ebewe’s injectable neurological products business. The unit will be folded into Sandoz, Novartis’ generics division. Several of Ebewe’s products — including paclitaxel, epirubicin, methotrexate, oxaliplatin, carboplatin, doxorubicin and gemcitabine — are essential components of standard-o...